| Document |
Document Title |
|
WO/2021/056105A1 |
Compositions and methods based on the use of mutated HIV-1 gp120 polypeptides having amino acid substitutions at positions 61, 105, 108, 375, 474, 475 and 476 are described. These mutated HIV-1 gp120 polypeptides, which make the HIV env ...
|
|
WO/2021/054351A1 |
Provided are: a novel membrane permeation enhancer which contains an amino acid-based surfactant and exhibits excellent safety; and a method for enhancing membrane permeation using this membrane permeation enhancer. The amino acid-based ...
|
|
WO/2021/049563A1 |
A photobase generator that comprises a compound including a first skeleton, which is represented by general formula (a), and a second skeleton, which includes a nitrogen atom that has been bonded to the combining site of the first skelet...
|
|
WO/2021/040441A1 |
The present invention relates to a method for preparing a biguanide-based compound with a high yield. More specifically, the present invention relates to a method for preparing a biguanide-based compound, the method comprising the steps ...
|
|
WO/2021/012274A1 |
The present invention provides a preparation method for metformin hydrochloride. The preparation method comprises: heating raw materials comprising dicyandiamide and dimethylamine hydrochloride by means of microwave, and making the two r...
|
|
WO/2021/008845A1 |
The invention relates to a new crystal modification of N-(aminoiminomethyl)-2-aminoethanoic acid, to crystal mixtures and to a method for producing the crystal modification and the crystal mixtures according to the invention.
|
|
WO/2021/008844A1 |
The present invention relates to a novel crystal modification of N-(aminoiminomethyl)-2-aminoethanoic acid and to a process for the production of said crystal modification.
|
|
WO/2021/008843A1 |
The present invention relates to novel crystal modification of N-(aminoiminomethyl)-2-aminoethanoic acid and to a process for producing said crystal modification.
|
|
WO/2021/008846A1 |
The invention relates to a method for producing N-(aminoiminomethyl)-2-aminoethanoic acid containing N-(aminoiminomethyl)-2-aminoethanoic acid in a thermodynamically metastable crystal modification.
|
|
WO/2021/002689A1 |
The present invention relates to a method for producing peramivir trihydrate, which is an inhibitor of neuraminidase infection, as an anti-influenza agent. According to the production method of the present invention, peramivir trihydrate...
|
|
WO/2020/262455A1 |
The present invention provides a means for increasing the solubility of even a poorly soluble amino acid without changing to an expensive peptide and also without changing the pH, and is characterized in that at least two kinds of amino ...
|
|
WO/2020/242948A1 |
The application is drawn to 18F-radiolabeled residualizing agents and biomolecules and methods for radiolabeling biomolecules with radioactive fluorine atoms. The biomolecules have an affinity for particular types of cells and may specif...
|
|
WO/2020/206534A1 |
The present technology generally relates to a chlorhexidine system comprising chlorhexidine or a salt thereof and metallic particles (such as silver and/or gold) wherein the chlorhexidine is conjugated to the surface of the metallic part...
|
|
WO/2020/210252A1 |
A process to extract carbon from hydrophobic waste comprises: combining the hydrophobic waste with an oxide of an active metal to form a storable, moisture-resistant feedstock for high-temperature processing; heating the feedstock in a f...
|
|
WO/2020/084599A4 |
The present invention relates to ammonium salts of partially fluorinated organic acids, represented by the general formula 1. The present invention relates also to a synthesis method of said salts as well as its use to the production of ...
|
|
WO/2020/191348A1 |
Therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A and arginine gingipain B, are disclosed, as well as the use thereof for the treatment of disorders associated with P. gingivalis ...
|
|
WO/2020/184797A1 |
The present invention relates to: an eco-friendly method capable of synthesizing an unnatural amino acid-based antibacterial and antibiotic preservative, which has excellent antibacterial and antibiotic performance, in a high yield and w...
|
|
WO/2020/179671A1 |
This invention provides: a curable resin composition including a specific polymer precursor, a nonionic compound B, and at least one compound selected from the group consisting of a polymerizable compound and a photosensitive compound, w...
|
|
WO/2020/176825A1 |
This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung canc...
|
|
WO/2020/084599A3 |
The present invention relates to ammonium salts of partially fluorinated organic acids, represented by the general formula 1. The present invention relates also to a synthesis method of said salts as well as its use to the production of ...
|
|
WO/2020/139300A2 |
The present invention relates to a pharmaceutical combination comprising granulocyte-colony stimulating factor (G-CSF) and a biguanide compound for treating a patient with cancer with a targeted therapy in combination with chemotherapies.
|
|
WO/2020/049365A3 |
The use of PREVORA brand topical dental solution (100 mg/ml chlorhexidine) sold by CHX Technologies, Inc., Toronto, Canada, to treat and/or prevent the advance of both dental decay (caries) and periodontal disease, simultaneously and in ...
|
|
WO/2020/120637A1 |
The application relates to a compound of formula (I) or a pharmaceutical salt thereof of formula (II), as well as to a process to obtain said compound and a process to obtain said salt. Additionally disclosed is the compound of formula (...
|
|
WO/2020/107500A1 |
The present invention provides a 2-(1-acyloxypentyl) benzoic acid salt formed by basic amino acid or aminoguanidine, a preparation method thereof, a pharmaceutical preparation containing the salt and the uses of the pharmaceutical prepar...
|
|
WO/2020/084599A2 |
The present invention relates to ammonium salts of partially fluorinated organic acids, represented by the general formula 1. The present invention relates also to a synthesis method of said salts as well as its use to the production of ...
|
|
WO/2019/109067A3 |
The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
|
|
WO/2020/061477A1 |
Disclosed are methods of treating creatine transporter deficiency, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that increases transport of a substrate by a mutant or wild-type cre...
|
|
WO/2020/060451A1 |
The invention concerns a method for making ammonium dinitramide from guanylurea dinitramide in one single process step. Guanylurea dinitramide is reacted with an ammonium sulfate in a reaction solution comprising water and optionally ace...
|
|
WO/2020/061367A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2020/022783A9 |
The present invention pertains to: a novel p62 ligand compound or a stereoisomer, solvate, hydrate, or prodrug thereof; and a pharmaceutical or food composition containing same as an active ingredient for preventing or treating protein a...
|
|
WO/2020/045326A1 |
The present invention provides a benzoic ester compound having an enteropeptidase inhibitory activity and a use of the compound as a medicine for the treatment or prevention of obesity, diabetes, etc. The compound is represented by formu...
|
|
WO/2020/022783A1 |
The present invention pertains to: a novel p62 ligand compound or a stereoisomer, solvate, hydrate, or prodrug thereof; and a pharmaceutical or food composition containing same as an active ingredient for preventing or treating protein a...
|
|
WO/2020/022784A1 |
The present invention relates to a novel p62 ligand compound, or a stereoisomer, solvate, hydrate, or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteopathies comprising same as an active ingredi...
|
|
WO/2019/233982A1 |
The present invention relates to new compounds of formula (I), and their uses.
|
|
WO/2019/232403A1 |
Described herein are compositions and methods for treating a disease or disorder associated with PI3K signaling. For example, such compositions can include use of modulators of glucose metabolism, use of at least one kinase in the insuli...
|
|
WO/2019/216322A1 |
Provided is a curable composition that contains an epoxy compound having two or more epoxy groups in each molecule thereof and a compound represented by general formula (1). In the formula, X is a group represented by general formula (1)...
|
|
WO/2019/199731A1 |
The present invention relates to crystalline forms of amphetamine-homoarginine conjugate 1- homoarginine-d-amphetamine, which is an amphetamine prodrug useful in the treatment of various diseases and conditions, and symptoms associated t...
|
|
WO/2019/170705A1 |
This invention relates to a compound according to general formula (IA), which acts as a selective cysteine protease inhibitor; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination p...
|
|
WO/2019/154769A1 |
The present invention relates to an improved process for the preparation of metformin hydrochloride, an important drug in the first line treatment of Type II Diabetes.
|
|
WO/2019/150323A1 |
Ionic liquids of creatine comprising a creatine anion and a cation., as well as their means of manufacture. Examples of the ionic liquids of creatine are choline creatinate, betaine ethyl ester creatinate and agmatine creatinate are desc...
|
|
WO/2019/100261A1 |
A metformin hydrochloride synthesis system and a preparation method therefor, the synthesis system comprising a reaction apparatus (20), the reaction apparatus (20) being provided with a feed opening and a reactant discharge opening, and...
|
|
WO/2019/088270A1 |
The present invention provides a compound that is highly safe and that is useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical compos...
|
|
WO/2019/084451A1 |
Food compositions or dietary supplements comprising an effective amount of an additive that comprises at least one oral hypoglycemic agent for the treatment, prevention, control and management of blood sugar and insulin spikes associated...
|
|
WO/2019/079707A1 |
The disclosure generally relates to the detection of symmetrical dimethylarginine (SDMA). More particularly, the disclosure relates to the detection of SDMA using a solid phase. The disclosure provides devices, reagents, kits and methods...
|
|
WO/2019/071353A1 |
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgi...
|
|
WO/2019/062661A1 |
The present invention relates to the field of pharmaceutical chemistry, and specifically, to a kind of oseltamivir derivatives that are neuraminidase inhibitors containing carbamido, a preparation method therefor, and medical uses thereo...
|
|
WO/2019/055280A1 |
The invention provides diethanolamine and morpholine salts of ursolic acid. Compositions containing the salts, and methods of using the salts are also provided.
|
|
WO/2019/047866A1 |
Disclosed are novel compounds, pharmaceutical compositions and methods of preparation and use thereof for treating disease affecting the central nervous system such as multiple sclerosis.
|
|
WO/2019/008027A1 |
The present disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 means a fluorine atom or a perhalogeno linear alkyl radical containing 1, 2 or 3 carbon atoms; R2 means a chlorine atom, ...
|
|
WO/2018/233326A1 |
A hydrogen sulfide donor in an organic salt form and a preparation method therefor. The hydrogen sulfide donor is a salt structure formed by organic compounds with an alkaline structure and hydrogen sulfide. The hydrogen sulfide donor ha...
|
